"Our physical trade-book business continues to be under some pressure, " Chief Executive William Lynch said in a conference call, adding that the New York company would continue to dedicate a large part of its financial resources to a digital future.
Zack Lynch, whose Neurotechnology Industry Organization represents 50 smaller companies pursuing treatments for brain disorders, worries that if the downturn continues, "we may lose an entire generation of potential brain drugs" as companies vanish.